- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.12. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 19.12.2025 | 557 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 19.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 19.12.2025ISIN NameCA74349R1055 PROPHECY... ► Artikel lesen | |
| 11.12. | NGM MARKET NOTICE: #25-119 Decision on delisting of Diagonal Bio AB from Nordic SME | 1 | Cision News | ||
| 11.12. | XFRA 9F1: AUSSETZUNG/SUSPENSION | 214 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILDIAGONAL BIO AB... ► Artikel lesen | |
| 11.12. | NGM MARKET NOTICE: #25-118 Trading halt in Diagonal Bio AB | 2 | Cision News | ||
| 04.03. | Diagonal Bio AB: Diagonal Bio has been approved for delisting from Nasdaq First North Growth Market | 334 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") today announces that Nasdaq has approved Diagonal Bio's application for delisting from Nasdaq First North Growth Market ("First North"). The... ► Artikel lesen | |
| 04.03. | Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME | 268 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or "the Company") has received conditional approval for listing on NGM Nordic SME ("NGM"). The first day of trading is planned for 19 March 2025. This means that... ► Artikel lesen | |
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 07.02. | Diagonal Bio AB: Diagonal Bio AB's rights issue of units oversubscribed | 471 | GlobeNewswire (Europe) | The subscription period in Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units of initially approximately SEK 6.0 million ended on 6 February 2025 (the "Rights Issue"). The Rights... ► Artikel lesen | |
| 29.01. | Diagonal Bio AB: Diagonal Bio announces positive pilot test results and secures order from StallZet | 186 | GlobeNewswire (Europe) | Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") announces an order valued at approximately SEK 150,000 from Daniel Redén, a renowned horse trainer at StallZet. The order comes as a result of... ► Artikel lesen | |
| 22.01. | Diagonal Bio AB: Diagonal Bio AB publishes investment memorandum prior to upcoming rights issue of units | 287 | GlobeNewswire (Europe) | The subscription period of Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, which was resolved on 23 December 2024 by the Board of Directors together with the resolution on... ► Artikel lesen | |
| 17.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.01.2025 | 942 | Xetra Newsboard | Das Instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY wird ex Kapitalmassnahme gehandelt am 17.01.2025 The instrument 2DV0 FR001400SVN0 DRONE VOLT SACA EO 1 EQUITY is traded ex capital adjustment... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 7,850 | +0,56 % | Cathie Wood's ARK makes strategic stock moves, buys Intellia and sells Roku | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,459 | -1,83 % | Cathie Wood's ARK buys Weride, Pacific Biosciences stocks, sells Ibotta | ||
| ATAI BECKLEY | 3,391 | +0,36 % | AtaiBeckley N.V.: AtaiBeckley Completes Redomiciliation to the United States | NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) ("AtaiBeckley" or "Company"), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing... ► Artikel lesen | |
| BIOMERIEUX | 110,00 | -0,18 % | BIOMERIEUX: bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health | ||
| BIO GREEN MED SOLUTION | 1,580 | +8,97 % | Bio Green Med Solution, Inc.: Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update | KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified... ► Artikel lesen | |
| GENUS | 29,400 | +0,68 % | Dividendenbekanntmachungen (06.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AIRTEL AFRICA PLC GB00BKDRYJ47 0,0216 GBP 0,0245 EUR ARMSTRONG WORLD INDUSTRIES INC US04247X1028 0,339 USD 0,2949 EUR ASHMORE GROUP... ► Artikel lesen | |
| ANAPTYSBIO | 43,600 | +0,46 % | GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße | DJ GSK und AnaptysBio verklagen einander wegen angeblicher Lizenzverstöße
Von Elena Vardon
DOW JONES--Der Arzneimittelhersteller GSK und das US-Biotechunternehmen AnaptysBio haben einen Rechtsstreit... ► Artikel lesen | |
| ABIONYX PHARMA | 3,505 | -3,58 % | ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m | Capital increase of approximately 1.8 million euros Subscription price: 3.10 euros Extension of financial visibility until the end of 2026
Regulatory News:
ABIONYX Pharma, (FR0012616852... ► Artikel lesen | |
| AKESO | 12,300 | 0,00 % | Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 0,525 | +1,94 % | XTL Biopharmaceuticals Ltd.: XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency | RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a notification letter from... ► Artikel lesen | |
| MEIRAGTX | 6,800 | +2,26 % | MeiraGTx Reports Third Quarter 2025 Financial and Operational Results | Entered into broad strategic collaboration with Eli Lilly and Company ("Lilly") in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company's AAV-AIPL1 program for treatment... ► Artikel lesen | |
| MAAT PHARMA | 4,740 | +3,72 % | Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): BUY | Original-Research: MaaT Pharma SACA - from First Berlin Equity Research GmbH
10.12.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,051 | -3,07 % | Isofol Medical AB: European Patent Office intends to grant a new patent for Isofol's arfolitixorin | GOTHENBURG, Sweden, November 13 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office (EPO) has issued an Intention to Grant notice regarding a... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 75,76 | 0,00 % | BTIG bestätigt Kaufempfehlung für Apogee Therapeutics angesichts positiver Aussichten | ||
| PRAXIS PRECISION MEDICINES | 297,12 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,004 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.